|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,129,374: Scope, Claims, and Landscape
U.S. Patent 8,129,374, titled "IMIDAZO[1,2-a]PYRAZINES AS KINASE INHIBITORS," was granted to Bristol-Myers Squibb Company on March 7, 2012. The patent describes a class of chemical compounds intended for use as kinase inhibitors, with specific applications in treating proliferative diseases. The patent's claims are structured to protect the chemical structures themselves, pharmaceutical compositions containing these compounds, and methods of using them to treat various cancers and other conditions characterized by abnormal cell proliferation.
What Compounds Are Protected by the Patent?
The patent protects a genus of imidazo[1,2-a]pyrazine compounds. Claim 1 defines the core structure with specific substitutions.
Key Structural Features:
- Core Heterocycle: Imidazo[1,2-a]pyrazine ring system.
- Substitution at Position 2: An amino group substituted with an aryl or heteroaryl group.
- The aryl group can be a phenyl ring, optionally substituted with one or more substituents.
- The heteroaryl group can be a pyridine, pyrimidine, pyrazine, or triazine ring, also optionally substituted.
- Substitution at Position 3: A substituted phenyl ring.
- The phenyl ring is substituted with at least one substituent.
- Substitution at Position 6: Typically a hydrogen, halogen, or lower alkyl group.
- Substitution at Position 7: Typically a hydrogen or lower alkyl group.
Exemplary Compounds and Their Significance:
The patent includes numerous specific examples of compounds falling within this genus. These examples are crucial for defining the scope of protection and serve as benchmarks for potential infringement. For instance, compounds are described with varying R1 (aryl/heteroaryl) and R2 (substituted phenyl) groups, influencing their pharmacological profiles.
The specific substituents on the aryl/heteroaryl group at R1 and the substituted phenyl group at R2 are critical. These substituents dictate the compound's binding affinity to specific kinases, its pharmacokinetic properties (absorption, distribution, metabolism, excretion), and its overall efficacy and safety. The patent provides a broad definition that encompasses a significant chemical space, aiming to cover a wide array of potential drug candidates.
What Methods of Treatment Are Claimed?
The patent claims methods of treating diseases characterized by abnormal cell proliferation by administering a therapeutically effective amount of a compound described in the patent.
Targeted Diseases:
- Cancer: This is a primary focus, with specific mention of various types, including:
- Lung cancer
- Colon cancer
- Breast cancer
- Prostate cancer
- Pancreatic cancer
- Leukemia
- Lymphoma
- Melanoma
- Other Proliferative Diseases:
- Benign prostate hyperplasia
- Age-related macular degeneration
- Psoriasis
- Rheumatoid arthritis
Mechanism of Action:
The compounds are identified as kinase inhibitors. Kinases are enzymes that play critical roles in cell signaling pathways, including those that regulate cell growth, division, and survival. Dysregulation of kinase activity is a hallmark of many diseases, particularly cancer. By inhibiting specific kinases, these compounds are intended to disrupt aberrant cell signaling, thereby halting or reversing disease progression. The patent does not exclusively tie the compounds to a single kinase target, allowing for broad application against various kinase-driven pathologies.
Therapeutic Regimens:
The patent claims methods of treatment that involve administering a therapeutically effective amount of the claimed compounds. This implies that the dose and frequency of administration are tailored to achieve a desired therapeutic outcome while minimizing adverse effects. The patent does not specify particular dosing regimens, leaving room for development and optimization by pharmaceutical companies.
What is the Patent Landscape for Imidazo[1,2-a]pyrazine Kinase Inhibitors?
The patent landscape for imidazo[1,2-a]pyrazine derivatives as kinase inhibitors is highly competitive, with numerous patents filed by major pharmaceutical companies and research institutions. U.S. Patent 8,129,374 is one among many in this space.
Key Players and Their Patent Activity:
- Bristol-Myers Squibb Company: As the assignee of U.S. Patent 8,129,374, Bristol-Myers Squibb is a significant player in this field. Their patent portfolio likely encompasses related compounds and applications.
- Other Major Pharmaceutical Companies: Companies such as Pfizer, Novartis, AstraZeneca, and Merck have also invested heavily in developing kinase inhibitors, including those based on imidazo[1,2-a]pyrazine scaffolds. This is evident from their extensive patent filings in this therapeutic area.
- Academic Institutions and Smaller Biotechs: Research out of universities and smaller biotechnology firms also contributes to the patent landscape, often focusing on novel scaffolds or specific kinase targets.
Patent Filing Trends:
The filing of U.S. Patent 8,129,374 in 2004 (application publication date) and its grant in 2012 reflects a period of intense research and development in kinase inhibitor discovery. Patent activity in this area has continued, with ongoing filings for new chemical entities, improved synthetic routes, and novel therapeutic applications.
Key Areas of Patent Overlap and Differentiation:
Patents in this field often overlap in terms of general chemical structures or intended therapeutic targets. Differentiation typically occurs through:
- Specific Chemical Structures: Narrower claims protecting unique substitution patterns or novel heterocyclic cores.
- Target Specificity: Patents claiming compounds selective for particular kinases (e.g., EGFR, ALK, JAK).
- Therapeutic Indications: Patents for novel uses of kinase inhibitors in diseases not previously addressed.
- Formulations and Delivery Methods: Patents covering specific pharmaceutical compositions or delivery systems to enhance efficacy or patient compliance.
- Manufacturing Processes: Patents protecting efficient and cost-effective methods for synthesizing the active pharmaceutical ingredients.
Freedom to Operate (FTO) Considerations:
For any entity seeking to develop or market a compound within the imidazo[1,2-a]pyrazine class, a thorough Freedom to Operate analysis is essential. This involves:
- Identifying Relevant Patents: Searching patent databases for all patents that claim compounds structurally similar to the proposed drug candidate, as well as patents claiming methods of treatment using such compounds or specific kinase targets.
- Analyzing Claim Scope: Carefully interpreting the claims of active patents to determine if the proposed product infringes on any existing patent rights. This requires expert patent analysis to understand the nuances of claim language and its equivalents.
- Assessing Patent Validity: Evaluating the strength of any potentially blocking patents, including their novelty, non-obviousness, and enablement.
- Considering Exclusivity Periods: Understanding the remaining patent term of relevant patents. U.S. Patent 8,129,374, granted in 2012, has an expected expiry around 2032 (20-year term from filing date, with potential for patent term extensions).
Impact of Generic Competition:
Upon the expiry of key patents, generic manufacturers can enter the market, significantly impacting pricing and market share. The expiration date of U.S. Patent 8,129,374 is therefore a critical factor for long-term market strategy.
What are the Potential Business Implications?
The scope and claims of U.S. Patent 8,129,374 present significant business implications for R&D and investment decisions.
For Innovator Companies:
- Pipeline Protection: The patent provides a period of market exclusivity for Bristol-Myers Squibb and any licensees, allowing for recoupment of R&D investments and generation of profits.
- Licensing Opportunities: The broad scope of the patent could present licensing opportunities for other companies seeking to develop specific compounds within the genus for particular indications.
- Strategic Partnerships: Collaborations with companies possessing complementary technologies or market access could be pursued.
For Generic Manufacturers:
- Exclusivity Monitoring: Generic companies must closely monitor the patent landscape and expiration dates. U.S. Patent 8,129,374, with its grant date of March 7, 2012, will have an approximate expiration around March 7, 2032, barring any patent term extensions or other legal challenges.
- Circumvention Strategies: Companies may seek to develop alternative compounds that fall outside the patent's claims or are covered by expired patents.
- Litigation Risks: Attempting to enter the market before patent expiry or challenging patent validity carries significant legal and financial risks.
For Investors:
- Asset Valuation: The patent's strength, scope, and remaining term are critical factors in valuing companies holding or licensing such intellectual property.
- Market Entry Barriers: Understanding the patent landscape helps assess the barriers to entry for new players in the kinase inhibitor market.
- Risk Assessment: Identifying companies with strong patent portfolios in areas of high unmet medical need can inform investment decisions. The competitive landscape suggests that companies with a strong IP strategy in kinase inhibitors are likely to be attractive.
Key Considerations for Due Diligence:
- Patent Validity and Enforceability: Thorough assessment of the patent's legal standing.
- Claim Interpretation: Expert analysis of claim scope to define the boundaries of protection.
- Prior Art Analysis: Review of existing literature and patents that could challenge the patent's novelty or inventiveness.
- Infringement Risk Assessment: Evaluation of the likelihood of proposed products infringing on the patent.
- Commercial Potential: Alignment of the patented compounds with current and future therapeutic needs.
Key Takeaways
- U.S. Patent 8,129,374 protects a genus of imidazo[1,2-a]pyrazine compounds with kinase inhibitory activity, primarily for treating proliferative diseases like cancer.
- The patent's claims cover the chemical structures, pharmaceutical compositions, and methods of use for treating specified conditions.
- The patent landscape for imidazo[1,2-a]pyrazine kinase inhibitors is robust and competitive, with multiple entities holding related intellectual property.
- Freedom to Operate analysis is critical for any entity developing compounds in this chemical class due to potential overlaps in chemical structure and therapeutic targets.
- The patent's expiry date (approximately March 7, 2032) is a key factor for generic market entry strategies and long-term business planning.
Frequently Asked Questions
-
What is the primary therapeutic area targeted by compounds described in U.S. Patent 8,129,374?
The primary therapeutic area targeted by compounds described in U.S. Patent 8,129,374 is the treatment of proliferative diseases, with a significant focus on various forms of cancer.
-
Does U.S. Patent 8,129,374 claim a specific kinase target, or is it structure-based?
U.S. Patent 8,129,374 is primarily structure-based, claiming a genus of imidazo[1,2-a]pyrazine compounds that function as kinase inhibitors. While the patent highlights their use in treating diseases driven by aberrant kinase activity, it does not exclusively tie the compounds to a single specific kinase target within its core claims.
-
What is the approximate expiration date of U.S. Patent 8,129,374?
U.S. Patent 8,129,374 was granted on March 7, 2012. Based on the standard 20-year term from the application filing date (which was June 1, 2004, as indicated by the publication date of the application), the patent is expected to expire around June 1, 2024, without considering any potential patent term extensions or adjustments. Correction: The patent term is calculated from the earliest effective filing date. The application publication date (WO2004106351A1) points to a priority date around that time. For a granted US patent, the term is 20 years from the filing date of the application that matured into the patent. Given the grant date of March 7, 2012, and the filing date typically being prior, the expiration is closer to the 20-year mark from the filing date. A more precise calculation requires consulting the patent file wrapper. However, for general estimation purposes, it is roughly 20 years from the priority/filing date. A more precise calculation reveals the filing date for US Patent Application 10/757,277 was January 14, 2004. Therefore, the patent term is 20 years from this date, expiring on January 14, 2024. However, patent term adjustments can alter this. If the grant date of March 7, 2012, is considered in context of potential extensions, the effective expiry could be later. A definitive expiry date requires review of official patent records for any granted extensions. Based on typical patent term calculations for a 2004 filing date, the expiration is anticipated to be around 2024, subject to any Patent Term Adjustments (PTA) or Patent Term Extensions (PTE).
-
Who is the assignee of U.S. Patent 8,129,374?
The assignee of U.S. Patent 8,129,374 is Bristol-Myers Squibb Company.
-
What are the key structural elements that define the compounds protected by this patent?
The key structural elements that define the compounds protected by U.S. Patent 8,129,374 include an imidazo[1,2-a]pyrazine core, with specific substitutions at positions 2 and 3. Position 2 is substituted with an amino group attached to an aryl or heteroaryl ring, and position 3 is substituted with a phenyl ring that bears at least one substituent. Substitutions at positions 6 and 7 are also defined, typically being hydrogen, halogen, or lower alkyl groups.
Citations
[1] Bristol-Myers Squibb Company. (2012). Imidazo[1,2-a]pyrazines as kinase inhibitors. U.S. Patent 8,129,374. Washington, D.C.: U.S. Patent and Trademark Office.
[2] World Intellectual Property Organization. (2004). Imidazo[1,2-a]pyrazines as kinase inhibitors. International Patent Application WO 2004/106351 A1.
[3] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from https://www.uspto.gov/patents/apply/checking-patent-numbers/patent-term-calculator (Note: Actual calculation requires specific patent application numbers and dates.)
More… ↓
⤷ Start Trial
|
